#United States #San Diego #Lennox-Gastaut #Epileptic Encephalopathies #Research Accelerator

Lennox-Gastaut Syndrome Foundation Launches Research Accelerator

On June 8, 2026, the Lennox-Gastaut Syndrome (LGS) Foundation announced an ambitious new initiative, the LGS and Associated DEE Research Accelerator. This groundbreaking effort aims to foster collaboration across various sectors, including industry, academia, and patient advocacy. The primary goal is to address the shared challenges in research focused on Lennox-Gastaut syndrome and related developmental and epileptic encephalopathies (DEE).

Lennox-Gastaut Syndrome is a severe form of epilepsy that typically appears in childhood. It is known for being treatment-resistant and can lead to lifelong cognitive and physical impairments. Despite the availability of some therapeutic options, many patients continue to experience seizures, and numerous individuals with LGS have other DEE diagnoses as well. The necessity for improved treatment strategies and clearer development pathways is more pressing than ever.

The newly launched Accelerator provides a platform for members to play an active role in addressing the collective obstacles encountered in this field. It will facilitate annual meetings and ongoing working groups, focusing on several critical priorities. One of the main objectives is to categorize patients according to biomarkers, which will support the assessment of treatment efficacy. Additionally, the initiative will utilize natural history data as real-world evidence in clinical trials. This data includes information from the Foundation's Collaborative Outcomes Registry (LGS-CORE)—a significant component of its broader initiative, Learn From Every Patient Database. This registry offers essential evidence that can be applied directly to clinical development.

Dr. Tracy Dixon-Salazar, President and CEO of the LGS Foundation, voiced her enthusiasm about the Accelerator, stating, "Progress in LGS has been slowed by problems no single organization can solve alone, including inconsistent endpoints and the lack of a shared evidence base. The Accelerator gives the community a place to fix those barriers together, so the science moves faster and patients see the benefit sooner."

Designed specifically for biopharmaceutical companies that are advancing therapies for LGS and associated DEE, the Accelerator enables these organizations to collaborate within a dedicated framework that also includes academic experts and representatives from the patient community.

Companies engaged in research and development relevant to LGS are encouraged to join this collaborative effort and can reach out to the LGS Foundation for more information.

For additional details about the LGS Foundation and their initiatives, visit LGSFoundation.org.

About the LGS Foundation

The Lennox-Gastaut Syndrome Foundation is resolutely committed to enhancing the lives of individuals affected by LGS and related developmental and epileptic encephalopathies through research, education, advocacy, and support. The Foundation aims to drive research that connects LGS with various other developmental and epileptic conditions that impact the communities it serves.